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Drug interactionAbstract Methotrexate (MTX) is an antifolate cytotoxic medication used to treat certain types of
cancer and at lower doses for rheumatic diseases. MTX has many serious adverse effects, such as
myelosuppression, hepatic, renal and pulmonary disorders. For safe and effective use of high dose
methotrexate (HDMTX) certain precautions should be followed. We present this case study with
short review to brieﬂy summarize the important practical issues related to HDMTX therapy.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Case
The case concerns a 21-year-old male patient with osteosar-
coma of the right tibia (Fig. 1), admitted to the oncology
department to receive chemotherapy in the form of 12 g/m2
high-dose methotrexate with leucovorin rescue. His current
medications include: 40 mg pantoprazole for a peptic ulcer,
160/800 mg trimethoprim–sulfamethoxazole (TMP–SMX) for
a urinary tract infection, 100 mg tramadol as needed for bone
pain, and 500 mg aspirin added by his dentist for dental pain.
The patient has shortness of breath secondary to pleural
effusion, as revealed by a chest X-ray. His vital signs are stable
with performance status of 1 and his kidney and liver functions
are normal.2. Questions
1. Is there any contraindication to methotrexate (MTX)
therapy in this case?
2. What are the potential major drug interactions found in
this case, and why?
3. What are the key precautions to prevent toxicity from
HDMTX therapy?3. Answers
1. Third-space compartments such as pleural effusion and
ascites are considered as contraindication to the
HDMTX therapy.
2. Many major drug–drug interactions can be found in this
case. Clinically relevant drug interactions include MTX
and pantoprazole, MTX with aspirin, and MTX with
TMP–SMX.
3. The general approach to prevent MTX toxicity includes
frequent MTX plasma level monitoring, urine alkalan-
ization, adequate hydration, and leucovorin rescue.
Figure 1 Magnetic resonance imaging of the proximal right tibia
osteosarcoma.
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Methotrexate (MTX) is an antifolate cytotoxic agent used to
treat certain types of hematological cancers, solid tumors,
and rheumatoid arthritis. HDMTX has many serious toxic
effects, such as myelosuppression, hepatic, renal, and pulmon-
ary disorders (Bleyer, 1977). HDMTX, deﬁned as MTX dose
of >1 g/m2, is given in combination with doxorubicin and a
platinum agent in most osteosarcoma protocols (Ferguson
and Goorin, 2001).
The presence of a third-space ﬂuid such as pleural effusions
or ascites is an important contraindication to the administra-
tion of HDMTX. Third-space ﬂuids lead to a prolonged
MTX plasma half-life and subsequently to prolonged exposure
to MTX, increasing the risk of toxicity. Drainage of third-
space ﬂuids before HDMTX is recommended to prevent toxic-
ity (Fox, 1979).
Many drug–drug interactions can compromise the safety of
HDMTX therapy by either delaying MTX elimination or aug-
menting its adverse effects. One major drug interaction is the
concurrent use of TMP–SMX with MTX; this is a serious
interaction that can be fatal in some cases. TMP–SMX is a
synergistic ﬁxed combination of trimethoprim and sulfameth-
oxazole in a 1:5 ratio respectively (Kielhofner, 1990). Both sul-
famethoxazole and trimethoprim are synthetic folate
antagonists. It is recommended to avoid such combination
or to stop TMP–SMX at least 3 days before starting MTX
(Al-Quteimat and Al-Badaineh, 2013).
Clinical evidence suggests that concomitant use of MTX
(primarily at high doses) with proton pump inhibitors (PPIs)
such as omeprazole, esomeprazole, and pantoprazole may
decrease methotrexate clearance, leading to elevated serum lev-
els of methotrexate, which in turn potentiate the risk of MTX
toxicity. Thus, combining MTX with PPIs such as pantopraz-
ole, in our case, is not recommended; if necessary, H2-blockers
such as ranitidine should be used alternatively (Bezabeh et al.,
2012).
NSAIDs can decrease renal perfusion and cause a rise in
serum MTX levels with the potential for toxicity (Baxter,
2011). MTX is also strongly protein bound and may be dis-
placed by NSAIDs (Kavanaugh and Broide, 2009).
According to a newly published systematic review, using
NSAID with HDMTX appears to be safe, provided appropri-
ate monitoring is performed. However, the use of anti-inﬂam-
matory doses of aspirin should be avoided (Colebatch et al.,
2012).
Many case reports have indicated reduction in the MTX
clearance when NSAIDs are used concurrently. Ketoprofen,
indomethacin, salicylate, ibuprofen, naproxen and diclofenacwere shown to produce different levels of toxicities in patients
treated with MTX (El-Sheikh et al., 2007). In this case, the
patient is receiving tramadol so it is reasonable to discontinue
aspirin to avoid this interaction.
HDMTX can result in severe toxicity if used inappropri-
ately, so certain precautions should be applied to promote safe
and effective use of HDMTX. These precautions include the
following:
5. Frequent monitoring of MTX level
Monitoring of plasma MTX level is very important to improve
the safety of HDMTX therapy. MTX levels should be fol-
lowed until the plasma level is less than 0.1 lM. Plasma
MTX levels are usually measured at 24, 48 and 72 h after start-
ing the MTX infusion (Gaies et al., 2012).
6. Elimination of third space ﬂuids before starting MTX therapy
The accumulation of third-space ﬂuids, as seen in pleural effu-
sion and ascites, will prolong MTX plasma half-life and
increase the risk of HDMTX toxicity. Drainage of third-space
ﬂuids before HDMTX is recommended to avoid toxicity (Fox,
1979).
7. Urine alkalanization
MTX and its metabolite 7-OH-MTX show, respectively, 20-
and 12-fold increased solubility when pH increases from 5 to
7 (Jacobs et al., 1976). Renal tubular precipitation of MTX
and 7-OH-MTX occurs when pH is lower than 5.7 (Fox,
1979). So it is recommended to keep the urine pHP 7.0 and
to maintain it in this range until plasma MTX levels decline
to less than 0.1 lM.
8. Using leucovorin rescue
Leucoverin rescue should be started within 24–36 h of the start
of the MTX infusion. Dose and frequency of leucoverin
depend on the HDMTX protocol used. Commonly used doses
of leucoverin are in the range of 10–15 mg/m2, given every 6 h
until plasma MTX levels are less than 0.2 lM (Olsen, 1991).
9. Adequate hydration
Adequate hydration is an essential part of HDMTX therapy to
promote diuresis and to prevent intratubular precipitation of
MTX. Intravenous ﬂuids of at least 2.5–3.5 L/m2 of IV per
day are recommended by most HDMTX regimens, starting
4–12 h before HDMTX infusion (Olsen, 1991; Widemann
and Adamson, 2006).
10. Using glucarpidase in patients with renal dysfunction
and delayed MTX clearance
Coadministration of drugs having the potential to displace
MTX from serum proteins and/or to reduce MTX clearance
should be avoided (Green, 2012). The concurrent use of TMP–
SMX and NSAIDs with MTX therapy has a well-documented
Practical issues with high dose methotrexate therapy 387major effect on MTX safety and should be avoided. Delayed
clearance of MTX was also reported with pyrazoles, aminogly-
cosides, probenecid, some penicillins, macrolides, omeprazole,
mezocillin, piperacillin, amphotericin B, and ciproﬂoxacin
(Gaies et al., 2012).
11. Conclusion
MTX has many serious and sometimes life-threatening side
effects that can be avoided by following special precautions
during HDMTX administration and post-treatment manage-
ment guidelines. Close monitoring, adequate hydration and
avoidance of interacting drugs are general principles applied
to prevent HDMTX toxicity that are common to all regimens.
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